New findings from two studies have tied use of the antiviral drug nirmatrelvir-ritonavir (Paxlovid) to a reduction in COVID-19 hospitalizations and death, as well as to faster resolution of symptoms and less use of healthcare resources.
Comments closedTag: Paxlovid
Paxlovid tied to fewer COVID-19 hospitalizations, reduced risk of long COVID
A new retrospective cohort study conducted in Dubai shows that the antiviral nirmatrelvir plus ritonavir, sold as Paxlovid, is tied to a 61% reduction in COVID-19 hospitalization and a 58% lower rate of long COVID.
Comments closedChanges in Paxlovid coverage raises concerns about affordability, access in N.B.
New Brunswick has taken steps to make Paxlovid more affordable for some people at higher risk of becoming severely ill or dying from COVID-19, now that the federal government has stopped supplying the anti-viral medication to provinces for free.
But the drug designed to reduce symptoms from an infection and shorten the period of illness remains out of reach for many, either because of the cost of about $1,400 for a five-day course, a lack of timely access, or reduced eligibility.
Comments closedWant To Prevent Long Covid? Should You Take Metformin Or Paxlovid?
Previously, I wrote about Paxlovid being underprescribed for treating acute Covid in patients at high risk for serious illness. The FDA granted an Emergency Use Authorization based on data showing that “Paxlovid significantly reduced the proportion of people with Covid-19 related hospitalization or death” by 88% compared to placebo.
In unvaccinated people, Paxlovid was also associated with a 26% lower risk of long Covid in a study by Ziyad Al-Aly.
The data on Paxlovid for those previously vaccinated is mixed. A smaller study from the University of California at San Francisco found no benefit in people who had been previously vaccinated.
Comments closedThe US Government Is Shutting Down A Key Covid Website
Tomorrow the US government agency responsible for biomedical and public health research, The National Institutes of Health, will shut down its Covid-19 ‘special populations’ website.
This site hosts a huge amount of information about how to treat covid and long covid in the immunocompromised and in people with HIV, cancer and similar immune supressing conditions – so-called ‘special populations.’
The site is going totally offline.
Comments closedOnce touted as a COVID-19 ‘game changer,’ Paxlovid is now a question mark for clinicians
If you catch the virus behind COVID-19 and you’re at a high risk of serious illness, there’s one major tool in a physician’s arsenal to keep you out of hospital: Paxlovid.
Pfizer’s antiviral drug was hailed as life-saving when it burst onto the scene midway through the pandemic. Clinical trials, conducted on people who’d never been vaccinated, showed it protected those vulnerable individuals from becoming dangerously sick, with a nearly 90 per cent reduction in the risk of hospitalization and death.
Comments closedWhat to do if you get COVID
That moment you’ve been dreading has arrived (perhaps not for the first time). You or someone in your household woke up with a sore throat maybe, or a nagging cough, and you did the swab. Double red line. Dammit.
What to do now? “Pax and relax”? Sit it out and hope for the best? Go about your normal business (as an increasingly alarming number of “experts” seem to be advising)? Is it really all down to a matter of good luck, good genes and good health? Not really. The available science says that there are differences in outcomes for people based on the choices they make after they get COVID, provided they move quickly.
Comments closedIvermectin warnings, a new COVID-19 antiviral, a changing threshold for care: These are the WHO’s updated treatment guidelines
The World Health Organization (WHO) has updated its guidelines for the treatment of COVID-19 patients, including categories of hospitalization risk to help doctors tailor treatment, and recommendations surrounding a new antiviral designed specifically to tackle the disease.
Comments closed